ISO 22442-2:2020 - Medical devices utilizing animal tissues and their derivatives - Part 2: Controls on sourcing, collection and handling Free Practice Test — 30 Questions

Question 1

When evaluating the suitability of animal-derived materials for medical device manufacturing under ISO 22442-2:2020, which combination of factors most comprehensively addresses the potential for infectious agent transmission from the source animal population to the final product?

Accepted Answer

Thorough epidemiological surveillance of the donor animal population, coupled with validated inactivation or removal processes for relevant agents and detailed traceability of all sourced materials.

Question 2

When assessing a medical device manufacturer\'s adherence to the sourcing controls outlined in ISO 22442-2:2020, which of the following approaches most effectively demonstrates comprehensive compliance with the standard\'s intent to mitigate adventitious agent transmission?

Accepted Answer

Maintaining a detailed, auditable record of the animal's origin, its health status at the time of collection, and a complete description of the collection and initial handling procedures.

Question 3

When evaluating the compliance of a medical device manufacturer utilizing bovine pericardium for a cardiovascular implant, what specific aspect of the sourcing and collection process, as stipulated by ISO 22442-2:2020, would be most critical to scrutinize to ensure the mitigation of adventitious agent transmission, particularly concerning spongiform encephalopathies?

Accepted Answer

The presence of a comprehensive risk assessment that explicitly details the geographical origin of the donor animals, the farming practices, veterinary oversight, and the specific inactivation or removal steps applied to the pericardium during processing.

Question 4

When evaluating the efficacy of controls implemented for medical devices utilizing bovine pericardium for cardiovascular valve repair, what specific aspect of the sourcing and collection process, as detailed in ISO 22442-2:2020, would be considered the most critical for mitigating the risk of adventitious agent transmission?

Accepted Answer

The establishment and maintenance of a comprehensive traceability system linking each batch of pericardium to the specific herd and individual animal of origin, including records of animal health and farm management practices.

Question 5

When developing a medical device that utilizes bovine pericardium for a cardiovascular implant, what is the paramount consideration for sourcing the animal material according to the principles outlined in ISO 22442-2:2020, specifically concerning the minimization of biological risks?

Accepted Answer

The geographical origin of the cattle and the TSE risk status of the sourcing country or region.

Question 6

When establishing a system for the sourcing of animal tissues for medical device manufacturing, what is the most critical factor to ensure compliance with the risk mitigation principles outlined in ISO 22442-2:2020, particularly concerning the potential for transmissible agents?

Accepted Answer

Comprehensive and documented animal health surveillance, including regular veterinary inspections and diagnostic testing for relevant pathogens, coupled with a system for reporting disease outbreaks.

Question 7

When developing a medical device that incorporates bovine pericardium for cardiovascular applications, what is the most critical initial step in establishing a compliant sourcing strategy according to ISO 22442-2:2020, considering the potential for adventitious agent transmission?

Accepted Answer

Verifying the epidemiological status of the country of origin concerning Transmissible Spongiform Encephalopathies (TSEs) and implementing controls based on this assessment.

Question 8

A medical device company plans to incorporate ovine pericardium into a novel cardiovascular implant. Their risk assessment identifies transmissible spongiform encephalopathy (TSE) as a significant potential hazard. According to the principles outlined in ISO 22442-2:2020, what is the most critical initial control measure to implement at the sourcing stage to mitigate this specific risk?

Accepted Answer

Verifying the TSE risk status of the geographical region from which the ovine animals were sourced.

Question 9

When establishing a supply chain for a novel medical device utilizing ovine brain tissue, what is the most critical initial consideration for selecting the country of origin, as stipulated by ISO 22442-2:2020, to ensure the safety of the final product?

Accepted Answer

The country's established national regulatory framework for medical device manufacturing and post-market surveillance.

Question 10

When assessing a manufacturer\'s adherence to the controls specified in ISO 22442-2:2020 for medical devices utilizing animal tissues, what constitutes the most fundamental and indispensable element for demonstrating compliance with the standard\'s requirements regarding sourcing, collection, and handling?

Accepted Answer

Comprehensive and accurate records detailing the entire lifecycle of the animal material, from sourcing to processing.

Question 11

When a medical device manufacturer utilizes bovine pericardium for a prosthetic heart valve, what specific control, as outlined in ISO 22442-2:2020, is paramount for ensuring the safety and efficacy of the final product, particularly in relation to the potential transmission of adventitious agents?

Accepted Answer

Establishing and maintaining a verifiable chain of custody for the pericardium from the point of collection to final processing.

Question 12

When evaluating potential animal sources for a novel medical device utilizing bovine tissues, what single factor, according to the controls outlined in ISO 22442-2:2020, carries the most significant weight in mitigating the risk of transmitting spongiform encephalopathy agents?

Accepted Answer

The official recognition of the sourcing country as having a negligible risk status for TSEs by a recognized international veterinary authority.

Question 13

When evaluating a manufacturer\'s compliance with ISO 22442-2:2020 concerning the sourcing and collection of bovine tissues for a novel regenerative medicine product, what fundamental element must be demonstrably in place to ensure effective control over potential adventitious agent transmission?

Accepted Answer

A fully integrated, documented system encompassing risk assessment, detailed procedural controls for sourcing and collection, and robust traceability mechanisms from donor animal to final processed material.

Question 14

When establishing a comprehensive system for controlling the sourcing, collection, and handling of animal tissues for medical devices, as mandated by ISO 22442-2:2020, what is the most critical element for ensuring effective risk mitigation against adventitious agents throughout the supply chain?

Accepted Answer

The implementation of a fully traceable system that documents the origin of the animal material from the herd or flock through all processing stages to the final device.

Question 15

When evaluating potential sources for animal-derived materials intended for medical devices, what is the paramount consideration for minimizing the risk of transmissible spongiform encephalopathy (TSE) transmission, as outlined in ISO 22442-2:2020?

Accepted Answer

The official TSE risk status of the country or region of origin of the source animals.

Question 16

When evaluating the suitability of animal tissues for incorporation into medical devices under ISO 22442-2:2020, what is the most critical factor to meticulously document and control regarding the animal source to mitigate the risk of adventitious agent transmission?

Accepted Answer

The detailed veterinary inspection report of the individual donor animal at the time of collection, alongside documented evidence of the geographical region's disease status and the species' overall health profile.

Question 17

When establishing a system for sourcing and collecting animal tissues for medical devices, as stipulated by ISO 22442-2:2020, what is the most critical element to ensure the integrity and safety of the raw material, beyond the health status of the donor animal itself?

Accepted Answer

Comprehensive and verifiable documentation of the entire supply chain, from animal origin to tissue collection.

Question 18

When evaluating potential animal sources for the manufacture of a novel biological scaffold intended for tissue regeneration, what fundamental criterion, as stipulated by ISO 22442-2:2020, must be the primary determinant in establishing the acceptability of a given geographical region\'s animal population for sourcing relevant tissues?

Accepted Answer

The prevalence of zoonotic diseases other than TSEs in the region's livestock.

Question 19

When assessing the effectiveness of controls implemented for sourcing and collecting animal tissues for medical device manufacturing, as outlined in ISO 22442-2:2020, which practice provides the most comprehensive assurance against the introduction of adventitious agents?

Accepted Answer

Establishing a complete and verifiable chain of custody for each animal unit from origin to processing.

Question 20

When evaluating the effectiveness of controls implemented for sourcing and collecting animal tissues for medical devices, as stipulated by ISO 22442-2:2020, what is the primary function of a comprehensive traceability system that links raw material to its donor animal and subsequent processing stages?

Accepted Answer

To facilitate the precise identification and isolation of materials from specific sources in the event of a quality issue or adverse event.

Question 21

When developing a quality management system for a medical device manufacturer utilizing ovine tissues, what constitutes the most comprehensive approach to fulfilling the sourcing and collection control requirements stipulated in ISO 22442-2:2020, ensuring the minimization of adventitious agent transmission?

Accepted Answer

Implementing a documented system for continuous assessment of the source animal herd's health status and the epidemiological profile of the geographical region, alongside detailed antemortem inspection and tissue harvesting procedures.

Question 22

When evaluating the suitability of a novel animal tissue source for a new class of medical devices, what fundamental control strategy, as outlined in ISO 22442-2:2020, should be prioritized to ensure the safety of the final product, considering potential adventitious agent transmission?

Accepted Answer

A comprehensive risk assessment that systematically identifies and evaluates potential hazards associated with the specific animal species, geographical origin, and intended use, leading to the implementation of targeted mitigation measures.

Question 23

When developing a medical device that utilizes bovine pericardium, what is the most critical control point mandated by ISO 22442-2:2020 to ensure the safety of the sourced biological material, considering the potential for adventitious agent transmission?

Accepted Answer

Documented evidence of the health status of the donor bovine population and the geographical origin of the animals, supported by a risk assessment.

Question 24

When evaluating a manufacturer\'s compliance with ISO 22442-2:2020 for a medical device incorporating ovine brain tissue, what is the most critical aspect to scrutinize regarding the sourcing and collection process to ensure the mitigation of transmissible agent risks?

Accepted Answer

The existence and thoroughness of a documented system detailing the health status of donor flocks, geographical origin, veterinary surveillance, and collection procedures.

Question 25

When evaluating the suitability of an animal source for tissue-derived medical devices under ISO 22442-2:2020, which combination of factors represents the most critical initial assessment for mitigating adventitious agent transmission?

Accepted Answer

Documented health surveillance of the donor animal population, geographical origin of the source animals, and the collection facility's adherence to Good Manufacturing Practices (GMP).

Question 26

When evaluating the suitability of animal-derived materials for medical device manufacturing, what fundamental control measure, as outlined in ISO 22442-2:2020, is paramount in mitigating the risk of adventitious agent transmission, particularly concerning TSEs, from the point of sourcing?

Accepted Answer

Rigorous validation of inactivation or removal steps during processing.

Question 27

When evaluating the control measures for sourcing and collecting ovine tissues for a novel regenerative medicine product, what integrated approach best aligns with the principles outlined in ISO 22442-2:2020 for mitigating transmissible agent risks?

Accepted Answer

Implementing a comprehensive animal health surveillance program for source flocks, coupled with stringent collection protocols that include immediate post-mortem tissue assessment and robust batch traceability from farm to processing.

Question 28

When assessing the adequacy of controls for a medical device incorporating bovine pericardium, what is the most critical factor to verify regarding the sourcing of the animal material, as stipulated by ISO 22442-2:2020?

Accepted Answer

Comprehensive documentation confirming the geographical origin of the cattle has a documented history of being free from specified animal diseases, supported by veterinary health authority declarations and the manufacturer's risk assessment.

Question 29

When developing a medical device that incorporates collagen derived from bovine bone, what fundamental risk management consideration, as outlined in ISO 22442-2:2020, should be prioritized during the initial sourcing and collection phase to effectively mitigate potential biological hazards?

Accepted Answer

Establishing a comprehensive traceability system for each batch of raw material from the donor animal to the finished device.

Question 30

Considering the principles outlined in ISO 22442-2:2020 for controlling the sourcing and collection of animal tissues, what is the most appropriate action for a manufacturer when a specific geographical region, from which they routinely source ovine tissues for medical device production, has recently reported a localized outbreak of a novel viral encephalopathy affecting cattle, even though ovine species are not known to be primary hosts for this particular pathogen and the affected tissues are not directly neurological?

Accepted Answer

Implement enhanced veterinary surveillance and consider temporary restrictions on sourcing from the affected geographical region until the epidemiological situation is fully clarified.

ISO 22442-2:2020 - Medical devices utilizing animal tissues and their derivatives - Part 2: Controls on sourcing, collection and handling Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 22442-2:2020 - Medical devices utilizing animal tissues and their derivatives - Part 2: Controls on sourcing, collection and handling Certification